Procalcitonin Is a Stronger Predictor of Long-Term Functional Outcome and Mortality than High-Sensitivity C-Reactive Protein in Patients with Ischemic Stroke

Molecular Neurobiology

Volumn 53, Issue 3, 2016, Pages 1509-1517

  Wang, Chao ^a   Gao, Li ^a   Zhang, Zhi Guo ^a   Li, Yu Qian ^a   Yang, Yan Long ^a   Chang, Tao ^a   Zheng, Long Long ^a   Zhang, Xing Ye ^a   Man, Ming Hao ^a   Li, Li Hong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute ischemic stroke; Functional outcome; High sensitivity C reactive protein; Mortality; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; PROCALCITONIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALCITONIN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SURVIVAL; AREA UNDER THE CURVE; BLOOD; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; AREA UNDER CURVE; BIOMARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CALCITONIN; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84961127363     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9112-7     Document Type: Article

References (32)

1. Zhang ZG, Wang C, Wang J, Zhang Z, Yang YL, Gao L, Zhang XY, Chang T et al (2014) Prognostic value of mannose-binding lectin: 90-day outcome in patients with acute ischemic stroke. Mol Neurobiol doi:10.1007/s12035-014-8682-0
2. Slot KB, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P (2008) Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 336:376–379
3. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H (2013) Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J Neuroendocrinol 25:771–778
4. Tu WJ, Zhao SJ, Liu TG et al (2013) Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurol Res 35(9):912–921
5. Vibo R, Kõrv J, Roose M, Kampus P, Muda P, Zilmer K, Zilmer M (2007) Free Radic Res. Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome. Free Radic Res 41(3):282–287
6. Yoldas T, Gonen M, Godekmerdan A, Ilhan F, Bayram E (2007) The serum high-sensitive C reactive protein and homocysteine levels to evaluate the prognosis of acute ischemic stroke. Mediators Inflamm 2007:15929
7. Shantikumar S, Grant PJ, Catto AJ, Bamford JM, Carter AM (2009) Elevated C-reactive protein and long-term mortality after ischaemic stroke: Relationship with markers of endothelial cell and platelet activation. Stroke 40:977–979
8. Di Napoli M, Godoy DA, Campi V et al (2011) C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score. Stroke 42:1230–1236
9. Huang Y, Jing J, Zhao XQ, Wang CX, Wang YL, Liu GF, Wang CJ, Liu LP et al (2012) High-sensitivity C-reactive protein is a strong risk factor for death after acute ischemic stroke among Chinese. CNS Neurosci Ther 18(3):261–266
10. Maruna P, Nedelnikova K, Gurlich R (2000) Physiology and genetics of procalcitonin. Physiol Res 49:S57–S62
11. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407
12. McGrane S, Girard TD, Thompson JL et al (2011) Procalcitonin and C-reactive protein levels at admission as predictors of duration of acute brain dysfunction in critically ill patients. Crit Care 15(2):R78
13. Mimoz O, Edouard AR, Samii K et al (1998) Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 24(2):185–188
14. Schiopu A, Hedblad B, Engström G et al (2012) Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population‐based study. J Intern Med 272(5):484–491
15. Katan M, Moon YP, DeRosa J et al (2014) Procalcitonin, copeptin and midregional pro-atrial natriuretic peptide as markers of ischemic stroke risk: the Northern Manhattan Study. Stroke 45(Suppl 1):A54–A54
16. Hatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54:541–553
17. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
18. Bamford J, Sandercock P, Dennis M et al (1991) Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521–1526
19. Brott T, Marler JR, Olinger CP, Adams HP Jr, Tomsick T, Barsan WG et al (1989) Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke 20:871–875
20. Zhang W, Zhang XA (2014) Prognostic value of serum lipoprotein(a) levels in patients with acute ischemic stroke. Neuroreport 25(4):262–266
21. Bonita RBR (1988) Modification of Rankin Scale: recovery of motor function after stroke. Stroke 19:1497–1500
22. Simon L, Gauvin F, Amre DK et al (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39(2):206–217
23. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477–1482
24. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL (2006) High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 166(19):2073–2080
25. Tamaki K, Kogata Y, Sugiyama D, Nakazawa T, Hatachi S, Kageyama G, Nishimura K, Morinobu A et al (2008) Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 35(1):114–119
26. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W et al (2011) Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 37:384–392
27. Luyt CE, Guérin V, Combes A et al (2005) Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171(1):48–53
28. Fluri F, Morgenthaler NG, Mueller B, Christ-Crain M, Katan M (2012) Copeptin, Procalcitonin and routine inflammatory markers—predictors of infection after stroke. PLoS One 7(10):e48309
29. Sacco RL, Boden-Albala B, Chen X, Lin IF, Kargman DE, Paik MC (1998) Relationship of 6-month functional outcome and stroke severity: implications for acute stroke trials from the Northern Manhattan Stroke Study [abstract]. Neurology 50(suppl 4):A327
30. Adams HP Jr, Davis PH, Leira EC et al (1999) Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 53:126–131
31. Castelli GP, Pognani C, Meisner M et al (2004) Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 8(4):R234
32. Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340:207–214